Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | HBB | P68871 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 5/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504353 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL2371134 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL2370652 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL1119124 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL2371891 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL2372027 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL2371874 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL2380101 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL11701621 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL2371273 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150258221-A1 | Paramagnetic Solid Lipid Nanoparticles (pSLNs) Containing Metal Amphiphilic Complexes For MRI | BRACCO IMAGING S.P.A. (IT) | 2015-09-17 | — | — | US | disclosed |
| US-7148371-B2 | Method for producing lysine derivative | AJINOMOTO CO., INC. (JP) | 2006-12-12 | — | — | US | disclosed |
| US-7012152-B2 | Method for producing lysine derivative | AJINOMOTO CO., INC. (JP) | 2006-03-14 | — | — | US | disclosed |
| US-20060004103-A1 | Method for producing lysine derivative | AJINOMOTO CO., INC. (JP) | 2006-01-05 | — | — | US | disclosed |
| US-6664412-B2 | Protecting amino group or amino group and carboxyl group of optically active 2-amino-6-methyl-6-nitroheptanoic acid with protecting group, reducing nitro group to synthesize 6,6-dimethyllysine and reacting this with acetic acid | AJINOMOTO CO., INC. (JP) | 2003-12-16 | — | — | US | disclosed |
| US-6469181-B1 | PREPARING 2-OXINDOLES AND N-HYROXY-2- OXINDOLES VIA REDUCTION OF 2-NITROARYLMALONATE DIESTERS WITHOUT ISOLATION OF INTERMEDIATES | CATALYTICA, INC. | 2002-10-22 | — | — | US | disclosed |
| EP-0809631-A4 | PROCESS FOR PREPARING 2-OXINDOLES AND N-HYDROXY-2-OXINDOLES | CATALYTICA INC (US) | 1998-07-08 | — | — | EP | disclosed |
| EP-0809631-A1 | PROCESS FOR PREPARING 2-OXINDOLES AND N-HYDROXY-2-OXINDOLES | CATALYTICA, INC. (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996023770-A1 | PROCESS FOR PREPARING 2-OXINDOLES AND N-HYDROXY-2-OXINDOLES | CATALYTICA, INC. (US) | 1996-08-08 | — | — | WO | disclosed |
| US-4035400-A | Preparation of omega-nitroalkanoic acids | TEXACO INC. (US) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258221-A1 | Paramagnetic Solid Lipid Nanoparticles (pSLNs) Containing Metal Amphiphilic Complexes For MRI | PLIN3, PEX3, SLC39A3 | LMNA 213/4885MEN1 2096/4885KMT2A 2932/4885 |
| US-20060004103-A1 | Method for producing lysine derivative | JMJD6, SIRT6, KDM6A | LMNA 1336/4885MEN1 1424/4885KMT2A 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.